Ionis Pharmaceuticals
IONS
353 hedge funds and large institutions have $5.72B invested in Ionis Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 112 increasing their positions, 119 reducing their positions, and 43 closing their positions.
35% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 43
4% more funds holding
Funds holding: 339 → 353 (+14)
6% less repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 119
11% less capital invested
Capital invested by funds: $6.45B → $5.72B (-$735M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
35% less call options, than puts
Call options by funds: $78.8M | Put options by funds: $120M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.1M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$30.3M |
| 3 |
Capital Fund Management (CFM)
Paris,
France
|
+$29.1M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$25M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$126M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$50.1M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$46.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$42.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$42.1M |
IONS Hedge Fund Activity: Q2 2015 in Review
353 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2015, worth a combined $5.72B — down 11% from $6.45B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new IONS positions and 43 closed out — a net gain of 15 holders — while 112 added to existing stakes and 119 trimmed.
The largest buyer was Vanguard Group, adding an estimated $36.1M. The largest seller was BlackRock Fund Advisors, cutting an estimated $126M.
- 353 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2015, up from 339 in Q1 2015.
- Funds reported $5.72B of Ionis Pharmaceuticals stock for Q2 2015, down 11% quarter-over-quarter.
- 58 funds opened new Ionis Pharmaceuticals positions in Q2 2015 and 43 closed out, a net change of +15 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2015 was Vanguard Group, an estimated $36.1M added.
- The largest Ionis Pharmaceuticals seller in Q2 2015 was BlackRock Fund Advisors, an estimated $126M sold.
Based on aggregated 13F filings for Q2 2015.